Diagnosis and therapy of ulcerative colitis: Fulminant attack;Diagnostik und theraoie der colitis ulcerosa: Fulminanter schub

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 9, 2004, Pages 1002-1006

  Hoffmann, J C ^a   Schwander, O ^a   Bruch, H P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; TACROLIMUS; ANTIINFECTIVE AGENT; IMMUNOSUPPRESSIVE AGENT;

COLON RESECTION; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG EFFICACY; ENDOSCOPY; HISTOPATHOLOGY; HUMAN; TOXIC MEGACOLON; TREATMENT INDICATION; ULCERATIVE COLITIS; ADULT; AGE; ARTICLE; CASE CONTROL STUDY; CHILD; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PARENTERAL NUTRITION; PROGNOSIS; PROSPECTIVE STUDY; REMISSION; RETROSPECTIVE STUDY; TIME;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; AGE FACTORS; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CHILD; COLECTOMY; COLITIS, ULCERATIVE; COLONOSCOPY; CONTROLLED CLINICAL TRIALS; CYCLOSPORINE; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; PARENTERAL NUTRITION; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 16544362730     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813519     Document Type: Conference Paper

References (69)

1. Hyde GM, Jewell DP. Review article: the management of severe ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 419-424 (III)
2. Marion JF, Present DH. The modern medical management of acute, severe ulcerative colitis. Eur J Gastroenterol Hepatol 1997; 9: 831-835 (IV)
3. Truelove SC, Witts LJ. Corisone in ulcerative colitis. Br Med J 1955; 2: 1041-1048 (IIa)
4. Carbonnel F, Lavergne A, Lemann M et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994; 39: 1550-1557 (III)
5. Carbonnel F, Gargouri D, Lemann M et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 273-279 (IIb)
6. Powell-Tuck J, Day DW, Buckell NA et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982; 27: 533-537 (III)
7. Chew CN, Nolan DJ, Jewell DP. Small bowel gas in severe ulcerative colitis. Gut 1991; 32: 1535-1537 (III)
8. Latella G, Vernia P, Viscido A et al. GI distension in severe ulcerative colitis. Am J Gastroenterol 2002; 97: 1169-1175 (IIb)
9. Almer S, Bodemar G, Franzen L et al. Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis. Lancet 1996; 347: 1731-1735 (III)
10. Chaudhuri A, Bekdash BA. Toxic megacolon due to Salmonella: a case report and review of the literature. Int J Colorectal Dis 2002; 17: 275-279 (IV)
11. Dallal RM, Harbrecht BG, Boujoukas AJ et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363-372 (III)
12. Medich DS, Lee KK, Simmons RL et al. Laparotomy for fulminant pseudomembranous colitis. Arch Surg 1992; 127: 847-852; discussion 852-853 (III)
13. Kaufman HS, Kahn AC, Iacobuzio-Donahue C et al. Cytomegaloviral enterocolitis: clinical associations and outcome. Dis Colon Rectum 1999; 42: 24-30 (III)
14. Rahbar A, Bostrom L, Lagerstedt U et al. Evidence of active cytomegalovirus infection and increased production of IL-6 in tissue specimens obtained from patients with inflammatory bowel diseases. Inflamm Bowel Dis 2003; 9: 154-161 (IIb)
15. Papadakis KA, Tung JK, Binder SW et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96: 2137-2142 (III)
16. Adani GL, Avital I, Ferraresso C et al. CMV infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001; 96: 3464-3465 (IV)
17. Cooper HS, Raffensperger EC, Jonas L et al. Cytomegalovirus inclusions in patients with ulcerative colitis and toxic dilation requiring colonic resection. Gastroenterology 1977; 72: 1253-1256 (III)
18. Aristizabal H, Acevedo J, Bolero M. Fulminant amebic colitis. World J Surg 1991; 15: 216-221 (IV)
19. Meyers S, Lerer PK, Feuer EJ et al. Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, double-blind clinical trial. J Clin Gastroenterol 1987; 9: 50-54 (III)
20. Kornbluth A, Present DH, Lichtiger S et al. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol 1997; 92: 1424-1428 (IV)
21. Lindgren SC, Flood LM, Kilander AF et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-835 (III)
22. Travis SP, Farrant JM, Ricketts C et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-910 (III)
23. Banez AV, Yamanishi F, Crans CA. Endoscopic colonic decompression of toxic megacolon, placement of colonic tube, and steroid colonclysis. Am J Gastroenterol 1987; 82: 692-694 (IV)
24. Present DH, Wolfson D, Gelernt IM et al. Medical decompression of toxic megacolon by "rolling". A new technique of decompression with favorable long-term follow-up. J Clin Gastroenterol 1988; 10: 485-490 (III)
25. Riedler L, Wohlgenannt D, Stoss F et al. Endoscopic decompression in "toxic megacolon". Surg Endosc 1989; 3: 51-53 (IV)
26. Lichtiger S, Present OH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845 (Ib)
27. Meyers S, Sachar DB, Goldberg JD et al. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double-blind clinical trial. Gastroenterology 1983; 85: 351-357 (Ib)
28. Oshitani N, Kitano A, Matsumoto T et al. Corticosteroids for the management of ulcerative colitis. J Gastroenterol 1995; 30 (Suppl 8): 118-120 (IIa)
29. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005-1013 (III)
30. Truelove SC, Willoughby CP, Lee EG et al. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 2: 1086-1088 (IIb)
31. Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998; 10: 411-413 (III)
32. Kjeldsen J. Treatment of ulcerative colitis with high doses of oral prednisolone. The rate of remission, the need for surgery, and the effect of prolonging the treatment. Scand J Gastroenterol 1993; 28: 821-826 (IIb)
33. D'Haens G, Lemmens L, Geboes K et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-1329 (Ib)
34. McIntyre PB, Powell-Tuck J, Wood SR et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986; 27: 481-485 (Ib)
35. Dickinson RJ, Ashton MG, Axon AT et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980; 79: 1199-1204 (Ib)
36. Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993; 88: 227-232 (Ib)
37. Seo M, Okada M, Yao T et al. The role of total parenteral nutrition in the management of patients with acute attacks of inflammatory bowel disease. J Clin Gastroenterol 1999; 29: 270-275 (IIb)
38. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27: 1210-1212 (Ib)
39. Dickinson RJ, O'Connor HJ, Finder I et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985; 26: 1380-1384 (Ib)
40. Mantzaris GJ, Hatzis A, Kontogiannis P et al. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994; 89: 43-46 (Ib)
41. Mantzaris GJ, Petraki K, Archavlis E et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 2001; 36: 971-974 (Ib)
42. Van Assche G, D'Haens G, Noman M et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-1031 (IIb)
43. Carbonnel F, Boruchowicz A, Duclos B et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 1996; 41: 2471-2476 (IIb)
44. Wenzl HH, Petritsch W, Aichbichler BW et al. Short-term efficacy and long-term outcome of cyclosporine treatment in patients with severe ulcerative colitis. Z Gastroenterol 1998; 36: 287-293 (IIb)
45. Stack WA, Long RG, Hawkey CJ. Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998; 12: 973-978 (IIb)
46. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 1587-1592 (IIb)
47. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999; 246: 339-346 (IV)
48. Actis GC. Cyclosporin for steroid-refractory ulcerative colitis. Am J Gastroenterol 2000; 95: 830 (III)
49. Actis GC, Volpes R, Rizzetto M. Oral microemulsion cyclosporin to reduce steroids rapidly in chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1999; 11: 905-908 (IIb)
50. Actis GC, Aimo G, Priolo G et al. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998; 4: 276-279 (IIb)
51. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17: 1273-1281 (III)
52. Fellermann K, Tanko Z, Herrlinger KR et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002; 8: 317-324 (III)
53. Fellermann K, Ludwig D, Stahl M et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998; 93: 1860-1866 (IIb)
54. Bousvaros A, Kirschner BS, Werlin SL et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000; 137: 794-799 (III)
55. Bousvaros A, Wang A, Leichtner AM. Tacrolimus (FK-506) treatment of fulminant colitis in a child. J Pediatr Gastroenterol Nutr 1996; 23: 329-333 (IV)
56. Fernandez-Banares F, Bertran X, Esteve-Comas M et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996; 91: 2498-2499 (IIb)
57. George J, Present DH, Pou R et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91: 1711-1714 (III)
58. Sood A, Kaushal V, Midha V et al. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002; 37: 270-274 (IIa)
59. Domenech E, Garcia-Planella E, Bernal I et al. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2002; 16: 2061-2065 (III)
60. Actis GC, Bresso F, Astegiano M et al. Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis. Aliment Pharmacol Ther 2001; 15: 1307-1311 (III)
61. Kader HA, Mascarenhas MR, Piccoli DA et al. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999; 28: 54-58 (III)
62. Sood A, Midha V, Sood N et al. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000; 19: 14-16 (Ib)
63. Higgins RM, Bloom SL, Hopkin JM et al. The risks and benefits of low-dose cotrimoxazole prophylaxis for Pneumocystis pneumonia in renal transplantation. Transplantation 1989; 47: 558-560 (Ib)
64. Hyde GM, Jewell DP, Kettlewell MG et al. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001; 44: 1436-1440 (IIb)
65. Treem WR, Davis PM, Hyams JS. Cyclosporine treatment of severe ulcerative colitis in children. J Pediatr 1991; 119: 994-997 (IIb)
66. Ramakrishna J, Langhans N, Calenda K et al. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1996; 22: 296-302 (III)
67. Probert CS, Hearing SD, Schreiber S et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52: 998-1002 (Ib)
68. Sawada K, Muto T, Shimoyama T et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003; 9: 307-321 (Ib)
69. Jo Y, Matsumoto T, Mibu RIida M. Addition of leukocytapheresis to steroid therapy: is it beneficial in recurrence of moderate-to-severe ulcerative colitis? Dis Colon Rectum 2003; 46: 3-9 (III)